Association between GWG and adverse neonatal outcomes in maternal age at delivery subpopulations. by Feifei Jiang (11795243)

Subjects:

Gender-wise distribution of CHIKV cases based on ELISA and RT-PCR. by Rajendra Prasad Chatterjee (18309672)

Case fatality and recovery rates based on different stratifications among included cases. by Reza Mehrizi (17664330)

Adverse event list. by Stefan Halbherr (21353882)

“…No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease −0.73; 95% CI; −2.1, 0.62; <i>p</i> = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; −2.6, 2.8; <i>p</i> > 0.999), Beck Depression Inventory (BDI) (mean decrease −1.27; 95% CI; −3.8, 1.3; <i>p</i> = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; −1.6, 2.4; <i>p</i> = 0.822). …”

Geometric significance. by Liangliang Yang (3814120)

Data Sheet 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.docx by Yi Li (1144)

Table1_Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.docx by Yanjing Zhang (401134)

“…The analysis revealed that 130 preferred terms (PTs) with significant disproportionality were based on the four algorithms, 67 (51.53%) of which were not included in the product labeling, affecting 6 systems and organs. …”

Schematic diagram of the changes in the significance of LSM factors in each prediction region based on the GWR-PSO-SVM coupled model. by Xianyu Yu (8562045)

Exposures showing statistically significant associations with CHD on exploratory analysis, and related exposures (full results in Appendix). by Helen Dolk (3169182)

Table1_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Image3_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.JPEG by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Table4_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Table2_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Table3_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Image2_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.JPEG by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Image1_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.JPEG by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Classification of cases based on a confidence interval and a relevance threshold. by Werner A. Stahel (10981211)

Descriptive statistics for pregnancy with the sample size based on valid cases. by Franziska Kremer (14691690)

Interactions learned by the BN are more significant than interactions between cells of the same type. by Ye Yuan (531126)

Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

Subjects: